Full Text of HB4450 103rd General Assembly
HB4450ham001 103RD GENERAL ASSEMBLY | Rep. Jackie Haas Filed: 3/22/2024 | | 10300HB4450ham001 | | LRB103 36645 RLC 71279 a |
|
| 1 | | AMENDMENT TO HOUSE BILL 4450
| 2 | | AMENDMENT NO. ______. Amend House Bill 4450 by replacing | 3 | | everything after the enacting clause with the following: | 4 | | "Section 5. The Illinois Controlled Substances Act is | 5 | | amended by changing Section 208 and by by adding Section 309.1 | 6 | | as follows: | 7 | | (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208) | 8 | | Sec. 208. (a) The controlled substances listed in this | 9 | | Section are included in Schedule III. | 10 | | (b) Unless specifically excepted or unless listed in | 11 | | another schedule, any material, compound, mixture, or | 12 | | preparation which contains any quantity of the following | 13 | | substances having a stimulant effect on the central nervous | 14 | | system, including its salts, isomers (whether optical | 15 | | position, or geometric), and salts of such isomers whenever | 16 | | the existence of such salts, isomers, and salts of isomers is |
| | | 10300HB4450ham001 | - 2 - | LRB103 36645 RLC 71279 a |
|
| 1 | | possible within the specific chemical designation; | 2 | | (1) Those compounds, mixtures, or preparations in | 3 | | dosage unit form containing any stimulant substances | 4 | | listed in Schedule II which compounds, mixtures, or | 5 | | preparations were listed on August 25, 1971, as excepted | 6 | | compounds under Title 21, Code of Federal Regulations, | 7 | | Section 308.32, and any other drug of the quantitative | 8 | | composition shown in that list for those drugs or which is | 9 | | the same except that it contains a lesser quantity of | 10 | | controlled substances; | 11 | | (2) Benzphetamine; | 12 | | (3) Chlorphentermine; | 13 | | (4) Clortermine; | 14 | | (5) Phendimetrazine. | 15 | | (c) Unless specifically excepted or unless listed in | 16 | | another schedule, any material, compound, mixture, or | 17 | | preparation which contains any quantity of the following | 18 | | substances having a potential for abuse associated with a | 19 | | depressant effect on the central nervous system: | 20 | | (1) Any compound, mixture, or preparation containing | 21 | | amobarbital, secobarbital, pentobarbital or any salt | 22 | | thereof and one or more other active medicinal ingredients | 23 | | which are not listed in any schedule; | 24 | | (2) Any suppository dosage form containing | 25 | | amobarbital, secobarbital, pentobarbital or any salt of | 26 | | any of these drugs and approved by the Federal Food and |
| | | 10300HB4450ham001 | - 3 - | LRB103 36645 RLC 71279 a |
|
| 1 | | Drug Administration for marketing only as a suppository; | 2 | | (3) Any substance which contains any quantity of a | 3 | | derivative of barbituric acid, or any salt thereof: | 4 | | (3.1) Aprobarbital; | 5 | | (3.2) Butabarbital (secbutabarbital); | 6 | | (3.3) Butalbital; | 7 | | (3.4) Butobarbital (butethal); | 8 | | (4) Chlorhexadol; | 9 | | (5) Methyprylon; | 10 | | (6) Sulfondiethylmethane; | 11 | | (7) Sulfonethylmethane; | 12 | | (8) Sulfonmethane; | 13 | | (9) Lysergic acid; | 14 | | (10) Lysergic acid amide; | 15 | | (10.1) Tiletamine or zolazepam or both, or any salt of | 16 | | either of them. | 17 | | Some trade or other names for a tiletamine-zolazepam
| 18 | | combination product: Telazol.
| 19 | | Some trade or other names for Tiletamine:
| 20 | | 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
| 21 | | Some trade or other names for zolazepam:
| 22 | | 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
| 23 | | [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon. | 24 | | (11) Any material, compound, mixture or preparation | 25 | | containing not more than 12.5 milligrams of pentazocine or | 26 | | any of its salts, per 325 milligrams of aspirin; |
| | | 10300HB4450ham001 | - 4 - | LRB103 36645 RLC 71279 a |
|
| 1 | | (12) Any material, compound, mixture or preparation | 2 | | containing not more than 12.5 milligrams of pentazocine or | 3 | | any of its salts, per 325 milligrams of acetaminophen; | 4 | | (13) Any material, compound, mixture or preparation | 5 | | containing not more than 50 milligrams of pentazocine or | 6 | | any of its salts plus naloxone HCl USP 0.5 milligrams, per | 7 | | dosage unit; | 8 | | (14) Ketamine; | 9 | | (15) Thiopental ; . | 10 | | (16) Xylazine: (N-2,6-dimethylpheny1)-5,6- | 11 | | dihydro-4H-1,3 thiazin-2-amine), including its isomers, | 12 | | esters, ethers, salts, and salts of isomers, esters, and | 13 | | ethers, whenever the existence of such isomers, esters, | 14 | | ethers, and salts is possible within the specific chemical | 15 | | designation. | 16 | | (d) Nalorphine. | 17 | | (d.5) Buprenorphine. | 18 | | (e) Unless specifically excepted or unless listed in | 19 | | another schedule, any material, compound, mixture, or | 20 | | preparation containing limited quantities of any of the | 21 | | following narcotic drugs, or their salts calculated as the | 22 | | free anhydrous base or alkaloid, as set forth below: | 23 | | (1) not more than 1.8 grams of codeine per 100 | 24 | | milliliters or not more than 90 milligrams per dosage | 25 | | unit, with an equal or greater quantity of an isoquinoline | 26 | | alkaloid of opium; |
| | | 10300HB4450ham001 | - 5 - | LRB103 36645 RLC 71279 a |
|
| 1 | | (2) not more than 1.8 grams of codeine per 100 | 2 | | milliliters or not more than 90 milligrams per dosage | 3 | | unit, with one or more active non-narcotic ingredients in | 4 | | recognized therapeutic amounts; | 5 | | (3) (blank); | 6 | | (4) (blank); | 7 | | (5) not more than 1.8 grams of dihydrocodeine per 100 | 8 | | milliliters or not more than 90 milligrams per dosage | 9 | | unit, with one or more active, non-narcotic ingredients in | 10 | | recognized therapeutic amounts; | 11 | | (6) not more than 300 milligrams of ethylmorphine per | 12 | | 100 milliliters or not more than 15 milligrams per dosage | 13 | | unit, with one or more active, non-narcotic ingredients in | 14 | | recognized therapeutic amounts; | 15 | | (7) not more than 500 milligrams of opium per 100 | 16 | | milliliters or per 100 grams, or not more than 25 | 17 | | milligrams per dosage unit, with one or more active, | 18 | | non-narcotic ingredients in recognized therapeutic | 19 | | amounts; | 20 | | (8) not more than 50 milligrams of morphine per 100 | 21 | | milliliters or per 100 grams with one or more active, | 22 | | non-narcotic ingredients in recognized therapeutic | 23 | | amounts. | 24 | | (f) Anabolic steroids, except the following anabolic | 25 | | steroids that are exempt: | 26 | | (1) Androgyn L.A.; |
| | | 10300HB4450ham001 | - 6 - | LRB103 36645 RLC 71279 a |
|
| 1 | | (2) Andro-Estro 90-4; | 2 | | (3) depANDROGYN; | 3 | | (4) DEPO-T.E.; | 4 | | (5) depTESTROGEN; | 5 | | (6) Duomone; | 6 | | (7) DURATESTRIN; | 7 | | (8) DUO-SPAN II; | 8 | | (9) Estratest; | 9 | | (10) Estratest H.S.; | 10 | | (11) PAN ESTRA TEST; | 11 | | (12) Premarin with Methyltestosterone; | 12 | | (13) TEST-ESTRO Cypionates; | 13 | | (14) Testosterone Cyp 50 Estradiol Cyp 2; | 14 | | (15) Testosterone Cypionate-Estradiol Cypionate | 15 | | injection; and | 16 | | (16) Testosterone Enanthate-Estradiol Valerate | 17 | | injection. | 18 | | (g) Hallucinogenic substances. | 19 | | (1) Dronabinol (synthetic) in sesame oil and | 20 | | encapsulated in a soft gelatin capsule in a U.S. Food and | 21 | | Drug Administration approved product. Some other names for | 22 | | dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro- | 23 | | 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or | 24 | | (-)-delta-9-(trans)-tetrahydrocannabinol. | 25 | | (2) (Reserved). | 26 | | (h) The Department may except by rule any compound, |
| | | 10300HB4450ham001 | - 7 - | LRB103 36645 RLC 71279 a |
|
| 1 | | mixture, or preparation containing any stimulant or depressant | 2 | | substance listed in subsection (b) from the application of all | 3 | | or any part of this Act if the compound, mixture, or | 4 | | preparation contains one or more active medicinal ingredients | 5 | | not having a stimulant or depressant effect on the central | 6 | | nervous system, and if the admixtures are included therein in | 7 | | combinations, quantity, proportion, or concentration that | 8 | | vitiate the potential for abuse of the substances which have a | 9 | | stimulant or depressant effect on the central nervous system. | 10 | | (Source: P.A. 100-368, eff. 1-1-18 .) | 11 | | (720 ILCS 570/309.1 new) | 12 | | Sec. 309.1. Xylazine exemptions. Notwithstanding the | 13 | | scheduling of xylazine as a Schedule III controlled substance, | 14 | | xylazine shall not be considered a controlled substance when: | 15 | | (1) used by licensed Illinois veterinarians dispensing or | 16 | | prescribing for, or administering to, a nonhuman species of a | 17 | | drug containing xylazine that has been approved by the U.S. | 18 | | Food and Drug Administration; | 19 | | (2) used by licensed Illinois veterinarians dispensing or | 20 | | prescribing for, or administering to, a nonhuman species that | 21 | | is permissible under the Federal Food, Drug, and Cosmetic Act; | 22 | | (3) manufactured, distributed, or used as an active | 23 | | pharmaceutical ingredient for manufacturing an animal drug | 24 | | approved under the Federal Food, Drug, and Cosmetic Act; | 25 | | (4) used by a licensed certified euthanasia technician |
| | | 10300HB4450ham001 | - 8 - | LRB103 36645 RLC 71279 a |
|
| 1 | | employed by a certified euthanasia agency; or | 2 | | (5) used by a wildlife biologist engaged in legal or | 3 | | authorized fieldwork under the indirect supervision of a | 4 | | veterinarian. ". |
|